AVANT to Report Second Quarter 2008 Financial Results on August 6, 2008
04 August 2008 - 7:56PM
Business Wire
AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) will release its
second quarter 2008 financial results before U.S. financial markets
open on August 6, 2008. AVANT executives will host a conference
call and live audio webcast at 9:00 am ET that same day. To access
the live call, dial 888-713-4199 (within the United States) or
617-213-4861 (outside the United States). The passcode for
participants is 98796339. A replay will be available approximately
two hours after the live call. To access the replay, dial
888-286-8010 (within the United States) or 617-801-6888 (outside
the United States). The passcode I.D. # is 22696598. The replay
will also be broadcast via the company's website
www.avantimmune.com approximately two hours after the live call.
About AVANT Immunotherapeutics, Inc. AVANT Immunotherapeutics, Inc.
is a NASDAQ-listed company discovering and developing innovative
vaccines and targeted immunotherapeutics for the treatment of
cancer, infectious and inflammatory diseases. AVANT focuses on the
use of tumor-specific targets and human monoclonal antibodies
(mAbs) to precisely deliver therapeutic agents through its novel
"targeted immunization" approach. In addition, AVANT is also
exploiting its access to proprietary human antibody technology for
development of therapeutics monoclonal antibodies (mAbs). AVANT's
deep product pipeline consists of products in varying stages of
development, with its lead candidate, CDX-110, currently undergoing
evaluation in a Phase 2/3 clinical trial in newly diagnosed
glioblastoma multiforme, one of the most aggressive forms of brain
cancer. AVANT also has several product candidates in its
development pipeline including: CDX-1307, a product based on its
proprietary APC Targeting Technology�, which is in two Phase 1
clinical trials for patients with advanced pancreatic, bladder,
breast and colon cancer; TP10, a complement inhibitor, in
development for transplantation and other indications; and Three
candidates based on its oral, rapidly-protecting, single-dose and
temperature-stable vaccine technology, including combination
vaccines for travelers, the military and global health needs. AVANT
licensed a rotavirus strain to GlaxoSmithKline that was used in the
development of Rotarix� for the prevention of rotavirus infection.
In addition, AVANT has two human food safety vaccines for reducing
salmonella infection in chickens and eggs which have been
commercialized.
Avant Immunotherapeutics (MM) (NASDAQ:AVAN)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Avant Immunotherapeutics (MM) (NASDAQ:AVAN)
Historical Stock Chart
Von Mai 2023 bis Mai 2024
Echtzeit-Nachrichten über Avant Immunotherapeutics (MM) (NASDAQ): 0 Nachrichtenartikel
Weitere AVANT Immunotherapeutics, Inc. News-Artikel